Study: Canadians Receptive to Pharma Cannabis Options

Canadians know of the benefits from medical treatments with cannabis, but still want confirmation from their doctors, according to a new survey made public on Tuesday (February 26). The poll commissioned by Tetra Bio-Pharma (TSXV:TBP,OTCQB:TBPMF), a life science cannabis firm, found two in three Canadians are willing to use pharmaceutical drugs with cannabis if prescribed […]

Paladin Board Green Lights Langer Heinrich Restart Study

After shuttering the Langer Heinrich uranium mine in August 2018, Paladin Energy’s (ASX:PDN) board has approved a prefeasibility study aimed at restarting the asset. Production ceased at the mine, located in the Namib Park region of Namibia, in 2017 due to depressed uranium prices, which made ongoing extraction uneconomical. As U3O8 prices began to recover […]

Novus Doses First Patient in Phase 1 Pharmacodynamics Study

Novus Therapeutics (NASDAQ:NVUS) has officially dosed the first patient in its phase 1 pharmacodynamics clinical trial to treat otitis media, which are inflammatory diseases of the middle ear, the company said on Monday (February 11). The study, called OP0201-C-001, is evaluating the company’s lead product candidate OP0201 for safety, tolerability and Eustachian tube (ET) function after […]

Kalytera Provides Update on Phase 2 Clinical Study Evaluating CBD in Prevention of Acute GVHD

Kalytera Therapeutics, Inc. (TSXV:KALY and OTCQB:KALTF) (the “Company” or “Kalytera”) today announced positive interim data from its ongoing Phase 2 clinical study evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”) following bone marrow transplant. GVHD is a life-threatening complication commonly occurring after bone marrow transplant procedures. GVHD occurs when the […]